Evaxion A/S – Sponsored ADR (NASDAQ:EVAX) Receives Average Rating of “Moderate Buy” from Analysts

Posted by Stanley Muller on Sep 4th, 2026

Shares of Evaxion A/S – Sponsored ADR (NASDAQ:EVAX – Get Free Report) have received a consensus recommendation of “Moderate Buy” from the six ratings firms that are covering the firm, Marketbeat Ratings reports. One investment analyst has rated the stock with a sell recommendation and five have given a buy recommendation to the company. The average 1 year price target among analysts that have issued a report on the stock in the last year is $11.00.

Separately, Weiss Ratings upgraded shares of Evaxion A/S from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Thursday, July 9th.

Get Our Latest Stock Report on Evaxion A/S

Hedge Funds Weigh In On Evaxion A/S

Several hedge funds and other institutional investors have recently modified their holdings of EVAX. Wesbanco Bank Inc. acquired a new stake in Evaxion A/S in the fourth quarter valued at about $48,000. Northwestern Mutual Wealth Management Co. bought a new stake in shares of Evaxion A/S during the 4th quarter valued at approximately $38,000. SmartHarvest Portfolios LLC bought a new stake in shares of Evaxion A/S during the 4th quarter valued at approximately $72,000. Annis Gardner Whiting Capital Advisors LLC acquired a new position in Evaxion A/S during the 1st quarter worth approximately $112,000. Finally, Renaissance Technologies LLC bought a new position in Evaxion A/S in the 1st quarter valued at approximately $146,000. Institutional investors own 11.04% of the company’s stock.

Evaxion A/S Price Performance

Shares of NASDAQ EVAX opened at $3.08 on Friday. The business has a fifty day moving average price of $3.10 and a two-hundred day moving average price of $3.55. The stock has a market capitalization of $25.69 million, a PE ratio of -2.55 and a beta of 0.26. The company has a debt-to-equity ratio of 0.69, a current ratio of 5.06 and a quick ratio of 5.06. Evaxion A/S has a fifty-two week low of $2.52 and a fifty-two week high of $12.15.

About Evaxion A/S

(Get Free Report)

Evaxion A/S is a clinical-stage biotechnology company headquartered in Copenhagen, Denmark, with additional operations in the United States. The company specializes in the development of immunotherapies and vaccines driven by its proprietary AI-based computational immunology platform. By leveraging machine learning and deep learning algorithms, Evaxion identifies and optimizes antigen targets for both therapeutic cancer vaccines and prophylactic vaccines against infectious diseases.

At the core of Evaxion’s business is its AI platform, which analyzes large datasets of genomic, proteomic and immunological information to predict immune-stimulating epitopes.